Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
A groundbreaking new drug to treat schizophrenia called Cobenfy, owned by pharmaceutical firm Bristol Myers Squibb, has been ...
Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure, the personal consumption expenditures ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback